Table 3.

Chronic GVHD characteristics at enrollment^*

	Joint/fascia manifestations at enrollment
	N	Present (n = 164)	N	Absent (n = 403)	P †
NIH joint/fascia score, median (IQR)	164	1 (1-2)	403	0 (0-0)	NA
Hopkins fascia score, median (IQR)	164	1 (0-1)	403	0 (0-0)	< .001
P-ROM total score, median (IQR)	98	23 (21-24)	231	25 (25-25)	< .001
Other site involvement, no. (%)
Skin	164	123 (75)	403	226 (56)	< 0.001
Skin sclerosis	164	86 (52)	403	38 (9)	< 0.001
Eye	164	87 (53)	403	189 (47)	0.18
Mouth	164	78 (48)	403	263 (65)	< 0.001
Liver	161	69 (43)	402	221 (55)	0.01
Gastrointestinal tract	164	54 (33)	403	123 (31)	0.58
Lung	164	79 (48)	403	210 (52)	0.40
Genital tract	147	21 (14)	376	35 (9)	0.10
NIH global score, no. (%)	164		403		< 0.001
Mild		4 (2)		49 (12)
Moderate		82 (50)		211 (53)
Severe		78 (48)		143 (35)
Symptom measure, median (IQR)
Lee muscle/joint subscale	145	7 (4-11)	336	3 (1-6)	< 0.001
Lee overall symptom score	145	24.3 (14.4-33.8)	338	18.7 (11-28.6)	< 0.001
10-point overall global rating	141	4 (3-6)	328	3.5 (2-5)	< 0.001
QOL measures, median (IQR)
FACT-G	139	76 (62-87)	322	81 (69-90.3)	0.003
SF36-MCS	137	47 (38-55.2)	317	51 (40.8-55.9)	0.06
SF36-PCS	137	37 (31.1-43.5)	317	40 (32.2-47.9)	0.002
Physical function measures, median (IQR)
HAP-MAS	140	73 (61-82)	326	73 (62-82)	0.74
HAP-AAS	140	63 (51-74)	326	62 (48-73)	0.57
Walk test (feet)	139	482 (415-568)	341	500 (404-575)	0.84
Grip test (lb)	157	55.8 (40-81.7)	377	61 (42.3-79.7)	0.71

^*IQR = interquartile range; NIH = National Institutes of Health; NA = not applicable; QOL = quality of life; FACT-G = Functional Assessment of Cancer Therapy-General; SF36 = hort Form 36; MCS = mental component score; PCS = physical component score; HAP = Human Activities Profile; MAS = maximum activity score; AAS = adjusted activity score.

^†Two-sample t-test or Chi-square test of independence.